ABSTRACT OBJECTIVES This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
T ype 2 diabetes is common in patients with heart failure, with reported prevalences of between 25% and 40% in trials and registries (1) (2) (3) (4) (5) . Heart failure patients with diabetes have worse symptoms, greater functional limitation, and higher rates of hospitalization and death than heart failure patients without diabetes (1) (2) (3) (4) (5) . The safety of established treatments for diabetes in patients with heart failure is uncertain. Sulfonylureas and insulin can cause hypoglycemia and it has been thought that metformin may increase the risk of lactic acidosis, although this has never been demonstrated (6, 7) .
Thiazolidinediones increase the risk of patients with diabetes developing heart failure (8, 9) . Thiazolidinediones also increase the risk of worsening of heart failure in patients with that condition (10, 11) .
Consequently, it is important that the safety of new treatments for diabetes is studied in patients with heart failure. One group of new treatments is the dipeptidyl peptidase (DPP)-4 inhibitors, which block the degradation of endogenous glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion in a glucose-dependent manner, suppress glucagon release, and slow gastric emptying (12) (13) (14) .
Three recent large, randomized controlled trials have reported conflicting evidence about the risk of heart failure with different agents in this class (15) (16) (17) .
None, however, characterized patients with heart failure at baseline or those developing heart failure during follow-up. Furthermore, none of the studies examined the effect of a DPP-4 inhibitor on left ventricular function. Here we report a study of the effects of the DPP-4 inhibitor vildagliptin in patients with heart failure and reduced ejection fraction (HFrEF) (18, 19) .
METHODS

The VIVIDD (Vildagliptin in Ventricular Dysfunction
Diabetes) trial was a prospective, randomized, double-blind, parallel-group trial comparing vildagliptin with placebo, added to standard therapy for 52 weeks in patients with type 2 diabetes and HFrEF. An McMurray et al. More than 90% of patients were treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; 78% with a beta-blocker; and 42% with a mineralocorticoid receptor antagonist.
Vildagliptin in Heart Failure
Baseline characteristics between treatment groups were well balanced, except that more patients in the vildagliptin treatment group had a history of smoking, prior hospitalization for heart failure, or chronic obstructive pulmonary disease.
FOLLOW-UP AND ADHERENCE. Overall, 101 patients (79%) assigned to vildagliptin and 100 patients (79%) assigned to placebo completed the 52-week follow-up as planned (Figure 2 ). There were 11 deaths (8.6%)
in the vildagliptin group and 4 deaths (3.2%) in the Table 2) . The intention to treat analysis is shown in Figure 3 . The pre-specified primary analysis Table 2 ).
OTHER ECHOCARDIOGRAPHIC FINDINGS. Changes in left ventricular volumes are shown in Table 2 and Figure 3 . McMurray et al.
Left ventricular end-diastolic volume increased
significantly with vildagliptin compared with placebo, and there was a trend in the same direction for end-systolic volume which was of borderline statistical significance (6-and 12-month volumes are shown in Online Table 3 ). There was a significant increase in stroke volume but no change in left ventricular wall thickness or mass. Table 3 ). In addition to heart failure (see above), these causes included acute coronary syndrome (6.3% vs. 0.8%, respectively) and a cardiac arrhythmia (3.9% vs. 1.6%, respectively).
Atrial fibrillation was detected on analysis of electrocardiograms in 6 vildagliptin-treated and 0 placebo-treated patients. Of the 11 deaths in the vildagliptin group, 7 were attributed to cardiovascular causes ( Table 3 ) (5 to cardiorespiratory arrest or sudden death and 2 to myocardial ischemia or infarction), No cases of pancreatitis were reported. There were no cases of angioedema confirmed by the adjudication committee.
OTHER FINDINGS. There were no significant differences between treatment groups for change from baseline to end of study in weight, heart rate, blood pressure, estimated glomerular filtration rate, or urinary albumin-to-creatinine ratio.
DISCUSSION
The primary goal of this safety study was to compare the effect of vildagliptin, 50 mg twice daily, with that of placebo, added to conventional treatment for diabetes, on LVEF in patients with HFrEF.
The study met the pre-specified objective of showing noninferiority, that is, it showed that vildagliptin, Similarly, adverse remodeling might also have been reflected in evidence of worsening heart failure, which was not seen.
On the other hand, the potentially harmful consequences of left ventricular enlargement, if real, cannot be ignored. Increase in left ventricular volume is associated with worse clinical outcomes, including mortality, in heart failure (21, 22) . This draws attention to the second surprising observation in the present study, which was of a higher mortality rate in the vildagliptin group. However, the total number of deaths was small and the imbalance in deaths attributable to a cardiovascular-cause death was 7 versus 4 (with none in the vildagliptin group attributed to worsening heart failure), respectively.
We believe, therefore, this imbalance most likely reflects the play of chance.
However, it is not certain that all DPP-4 inhibitors are safe in patients with heart failure. In the KEY WORDS diabetes, heart failure APPENDIX For supplemental tables, please see the online version of this paper.
